Levofloxacin News
Susceptibility Testing of Clinical Isolates of Pseudomonas aeruginosa to Levofloxacin, Moxifloxacin, and Gatifloxacin as a Guide to Treating Pseudomonas Ocular Infections
Purpose. Pseudomonas aeruginosa ocular infections most frequently originate from an environmental source; successful treatment with various ocular antibiotics is well established. However, emergence of resistant clones to...
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin
Two of the most serious respiratory tract infections are community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB). The most common pathogens found in patients with these infections are Haemophilus...
Levaquin ® FDA approved for short-course treatment of acute bacterial sinusitis
The U.S. Food and Drug Administration (FDA) have approved a new five-day, 750 mg once-daily regimen for LEVAQUIN® ( levofloxacin) tablets to treat acute bacterial sinusitis. This regimen is available in the convenient Leva - pak...
Azithromycin Microspheres and Levofloxacin Equally Effective in COPD: Presented at ATS
Single-dose azithromycin-microspheres (AZ-M) and 7-day Levofloxacin (LEV) are equally effective treatments for acute exacerbation of chronic bronchitis (AECB) without regard to underlying severity of chronic obstructive pulmonary...
New Treatment Successful against Persistent H. pylori
Levofloxacin-based therapy appears to offer the best treatment for persistent Helicobacter pylori infection, according to a study published in the April issue of the American Journal of Gastroenterology.